Results 41 to 50 of about 114,683,953 (299)

Facial Cosmetic Therapy Use Among Patients With Systemic Sclerosis: An Australian Cohort Study

Arthritis Care &Research, EarlyView.
Objective Systemic sclerosis (SSc) is associated with numerous facial manifestations for which patients may engage in cosmetic therapies. It is unclear how patients with SSc use these therapies. This study sought to characterize patient engagement and experiences with cosmetic therapies for SSc‐related and non‐SSc–related facial changes.
Zachary Warren, Diane Apostolopoulos, Gene‐Siew Ngian, Amanda M. Saracino, Laura Ross, Nava Ferdowsi, Jennifer Walker, Cindy Hall, Kim Griggs, Susanna Proudman, Wendy Stevens, Joanne Sahhar   +11 more
wiley   +1 more source

Treatment Efficacy of Electromyography versus Fiberscopy-Guided Botulinum Toxin Injection in Adductor Spasmodic Dysphonia Patients: A Prospective Comparative Study

The Scientific World Journal, 2014
Introduction. This study prospectively evaluates and compares the treatment efficacy of botulinum toxin injection under electromyography guidance (EMG group) and percutaneous botulinum toxin injection under flexible fiberscopic guidance (fiberscopy group)
Jae Wook Kim, Jae Hong Park, Ki Nam Park, Seung Won Lee   +3 more
doaj   +1 more source

An Update on the Cosmetic Use of Botulinum Toxin: The Pattern of Practice among Korean Dermatologists

Toxins, 2022
The efficacy and safety of botulinum toxin injection have made it a popular aesthetic procedure worldwide. A cross-sectional survey was performed in order to determine the pattern of type A botulinum toxin injections in cosmetic practice, for which an 18-
Nark-Kyoung Rho, Kwang-Ho Han, Hei-Sung Kim   +2 more
doaj   +1 more source

Immunogenicity of botulinum toxins [PDF]

Journal of Neural Transmission, 2012
Botulinum neurotoxins are formulated biologic pharmaceuticals used therapeutically to treat a wide variety of chronic conditions, with varying governmental approvals by country. Some of these disorders include cervical dystonia, post-stroke spasticity, blepharospasm, migraine, and hyperhidrosis.
Naumann, Markus, Boo, Lee Ming, Ackerman, Alan H., Gallagher, Conor J.   +3 more
openaire   +3 more sources

Intelligent Micro/Nanorobots for Targeted Interventional Therapy: From Bench to Clinic

Advanced Robotics Research, EarlyView.
Zirui Zhang et al. reviewed the application and challenges of mobile nanomachines in interventional therapy. By converting exogenous energy, including chemical, magnetic, optical, and ultrasonic sources, into mechanical forces, micro/nanorobots (MNRs) enable precise actuation at unprecedented scales. Evolving far beyond traditional drug delivery, these
Zirui Zhang, Yu Dong, Yongsheng Du, Rui Gao, Lin Zhang, Fei Tong   +5 more
wiley   +1 more source

BOTOX injection to treat strabismus after infant botulism type B infection

American Journal of Ophthalmology Case Reports, 2020
Purpose: The significance of botulinum toxin to ophthalmologists is twofold. Botulism, a medical emergency, frequently presents with ocular findings including blurred vision, diplopia, ptosis, and photophobia as a result of the neurotoxin produced by ...
Sarah G. Bonaffini, Victoria Cocozza, Jing Jin   +2 more
doaj   +1 more source

YAP1‐Driven Pathogenic Fibro‐Adipogenic Progenitors Secrete IL‐6 and FGF21 to Mediate Muscle‐Bone Crosstalk and Promote Bone Loss

Advanced Science, EarlyView.
Fibro‐adipogenic progenitors (FAPs) in atrophic muscle undergo YAP1‐driven pathogenic activation, secreting IL‐6 and FGF21 as bone‐catabolic myokines that mediate muscle‐bone crosstalk and promote bone loss. Genetic or pharmacological targeting of this YAP1‐FAP‐myokine axis rescues skeletal deterioration, identifying FAP‐derived myokines as therapeutic
Xiaoyu Cai, Tao Xu, Rui Ma, Weikun Meng, Shutao Gao, Yakefu Abulizi, Alafate Kahaer, Chuanhui Xun, Maierdan Maimaiti, Rui Cao, Weidong Liang, Polati Maimaiti, Qiang Deng, Jun Sheng, Ting Wang, Mingchong Liu, Weibin Sheng   +16 more
wiley   +1 more source

In Vivo Model of Short-Term Efficacy and Favorable Safety of Botulinum Toxin Type E Compared with Type A

Toxins
Botulinum toxin suppresses neurotransmitter release, thereby inhibiting muscle contraction and inducing flaccid paralysis. Botulinum toxin type A (BoNT/A) is widely used for neuromuscular blockade but, upon repeated administration, may cause long-lasting
Jeong-Sun Nam, Daewon Yoon, Yujin Kim, Su-Young Kim, Jae-Young Kim, Yoonkyoung Cha, Joon Seok, Beom Joon Kim   +7 more
doaj   +1 more source

Contralateral Upper Limb Weakness Following Botulinum Toxin A Injection for Poststroke Spasticity

Acta Médica Portuguesa, 2020
Botulinum toxin type A has been approved for spasticity management in poststroke patients. The adverse effects are generally of two types: those related to local injection; and those related to the systemic effects from spread of the toxin ...
Alexandre Camões- Barbosa, Inês Mendes Ribeiro, Luisa Medeiros   +2 more
doaj   +1 more source

The Effect of Botulinum Toxin Type A in Patients with Essential Blepharospasm

Acta Clinica Croatica, 2022
The aim of this study was to determine the effect of botulinum toxin type A and satisfaction in patients with essential blepharospasm. The study included 12 subjects suffering from essential blepharospasm who received therapy with botulinum toxin type ...
Klara Gaćina, Mladen Lešin, Dean Sarajčev, Nina Rotim   +3 more
doaj   +1 more source